The market did a lot better to start the week than I would have thought and that strength continues today. At this point, I think everyone does not really trust the market (I fall in that camp) but does that mean then that the sellers on this pop get burned? Everyone expects the move higher […]
November 19 Biotech Update
This should be a relatively slow week but with ASH late breaking abstracts coming out later, it might not be completely devoid of news. There is a little more hope for the sector than the middle of last week. We have had a couple of strong days, although one could argue this has just brought […]
October 25 Biotech Update
Yesterday was brutal and there is really little to say about it as we are clearly in the middle of a massive correction if not outright bear market. I suspect that we are closer to the end than the beginning but that does not mean we could not see another 10% lower from these levels […]
October 17 Biotech Update
Yesterday was obviously a great day for the sector with everything higher and by a lot. It is not stunning to see some pullback from that move but if there is truly a reinvigorated sector, then you would want to see this red opening reverse into a green day to turn yesterday from a one-off […]
October 15 Biotech Update
Tell me if you heard this story before. Merger Monday and nothing happens in biotech. We have essentially run out of excuses as it was the political uncertainty and then it was tax reform. Neither are issues at the moment and we still have nothing happening. Are valuations in public companies still too high? Have […]
September 24 Biotech Update
An interesting start to the week, although we still like real M&A or business development. Unlike previous weeks, however, there is actually some interesting news to discuss. The sector is green and outperforming the broader market but the move seems pretty isolated so ideally this green will broaden as the day continues. 1. The big […]
September 20th Biotech Update
Still a boring market in terms of news. The sector appears to have successfully defended the bottom end of its range but one could argue it done so simply by performing in-line with a strong broad market. Given the broader strength it would have been an awful signal to breakdown but regardless of the reason, […]
September 17 Biotech Update
Not a great start to the week in terms of trading as it looks like we are set to retest the bottom on the range (yet again). As long as the market does not start a larger move lower, there is nothing to think that the range will not hold again but as with any […]
September 12th Biotech Update
The sector is certainly struggling and its inability to generate any consistent buying interest after the sell-off is certainly worrisome. All of that being said there are so many names that have been red everyday that there has to be a snap back rally at a minimum. CELG has lost over $1.2B in market cap […]
September 11th Biotech Update
While we have another snoozer of a day in biotech land, it does provide some insight into the trading bias of the sector and it remains negative. You would think that the path of least resistance would be to test the upper end of the recent range given the sharp sell-off but at this point […]
September 10 Biotech Update
There is nothing going on in the sector. No real news. No new deals. You would have thought that September would bring about some news but it seems like we are stuck in the summer pattern. It looks like that breakout failed its test and the next key to watch is what happens at 120 […]
August 2 Biotech Update
The sector continues to hold up in terms of price action relative to the broader market. If the market can at least stabilize, the sector has a good chance to eventually regain and perhaps break through recent highs. Obviously, all bets are off if the broader market collapses. My inclination is that the tech and […]
July 31 Biotech Update
I am still trying to catch up on all the earnings and happenings last week but I wanted to talk about two broad observations. In some ways, I benefited from not being able to watch the price action last week and only really looked at the news. In general, the price action does not reflect […]
July 17 Biotech Update
The lack of news continues as well as a generally weak market. While it certainly was not strong yesterday (and to start today), it feels more like indifference than a strong push by the bears. This does not mean it could not morph into something more meaningful but at this point it seems more like […]
July 16 Biotech Update
Not a lot of news this morning so I will keep it quick. We will have some earnings but large pharma tends to not be a leading indicator for biotech earnings but we will certainly watch to see if there is anything meaningful in the earnings or how the respective stocks react to the earnings. […]
July 12 Biotech Update
I think we are entering a lull in the sector as we are approaching earnings seasons. In general, this tends to be a better season than the first but that also means expectations are a little higher. A good earning season would see no major misses and at least a couple beat and raises from […]
PSTI – Placenta Stem-Cells Brings Hope to PAD-Peripheral Artery Disease Patients
Intermittent Claudication or as called IC is a peripheral artery disease (PAD) caused by fatty deposits that accumulate in the arteries of the leg and reduce blood flow to exercising muscle and is generally a reliable indicator of occlusive arterial disease, which lead to a discomfort, weakness and a leg pain after any effort like exercise, […]
June 1 Biotech Update
Happy ASCO days. The first day tends to be slow as news as it is information sessions, although later in the day we get some important CART data. In any case, by Monday we should have some interesting data to dissect. 1. CELG and BLUE have their BCMA CART data this evening. Expectations are high […]
May 21 Biotech Update
So it looks like the trade war with China is off, which should be good for the market in general. Whether that risk on appetite will translate into the biotech sector is another question as they are not a real beneficiary of the lack of a trade deal. That being said they certainly sold off […]
May 2 Biotech Update
It does not seem like today is going to be a good day for the sector but we have to see how it all plays out. There is some important earnings that might have import for the broader sector. 1. GILD had an absolute awful quarter. The only positive was that the CART crushed expectations […]
